Human CXCL5/ENA-78 DuoSet ELISA, 15 Plate

• Reactivity: Hu
• Applications: ELISA
• Conjugate: Biotin

Human CXCL5/ENA-78 DuoSet ELISA, 15 Plate Summary

• Source: N/A
• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: CXCL5

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human CXCL5/ENA-78 DuoSet ELISA, 15 Plate

• chemokine (C-C motif) ligand 5
• C-X-C motif chemokine 5
• CXCL5
• CXCL5/ENA-78
• ENA78
• ENA-78
• ENA-78(1-78)
• Epithelial-derived neutrophil-activating protein 78
• Neutrophil-activating peptide ENA-78
• neutrophil-activating protein 78
• SCYB5ENA78

Background

CXCL5/Epithelial Cell-derived Neutrophil-activating Peptide (ENA-78), is a member of the CXC subfamily of chemokines. Full-length CXCL5/ENA-78 is 114 amino acids (aa) in length with a predicted molecular weight of 12 kDa. Following the removal of the signal peptide, bioactive CXCL5/ENA-78 is 78 aa in length. CXCL5/ENA-78 can be N-terminally cleaved by Cathepsin G and Chymotrypsin to CXCL5/ENA-74 (74 aa) and CXCL5/ENA-70 (70 aa), which show increased potency relative to CXCL5/ENA-78. While murine LIX was thought to be an ortholog to human CXCL5/ENA-78, genome-wide analysis and a consensus in the field suggests that human CXCL5/ENA-78 does not have a true murine ortholog. CXCL5/ENA-78 is upregulated at sites of inflammation and is expressed by multiple hematopoietic cell types, fibroblasts, endothelial cells, vascular smooth muscle cells, and adipocytes. It acts as a chemoattractant for neutrophils, has angiogenic properties, and contributes to cancer progression.

Publications for CXCL5/ENA-78 (DY254)(24)

Publications using DY254

• Molczyk, C;Sturgeon, R;Saxena, S;Johnsson, E;Bhatia, R;Bhyrabhatla, N;Kumar, S;Batra, SK;Singh, RK; Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer bioRxiv : the preprint server for biology 2025-06-28 [PMID: 40667309] (Human)
• Christopher, BN;Golick, L;Basar, A;Reyes, L;Robinson, RM;Angerstein, AO;Krieg, C;Hobbs, GA;Guttridge, DC;O'Bryan, JP;Dolloff, NG; Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in Pancreatic Cancer Biomolecules 2025-04-30 [PMID: 40427538] (Human)
• Somova, M;Simm, S;Ehrhardt, J;Schoon, J;Burchardt, M;Pinto, PC; SARS-CoV-2 Spike Protein Amplifies the Immunogenicity of Healthy Renal Epithelium in the Presence of Renal Cell Carcinoma Cells 2024-12-10 [PMID: 39768130] (ELISA, Human)
• Zobel, CM;Wenzel, W;Krüger, JP;Baumgarten, U;Wagelöhner, T;Neumann, N;Foroutan, B;Müller, R;Müller, A;Rauschning, D;Schü beta ler, M;Scheit, L;Weinreich, F;Oltmanns, K;Keidel, F;Koch, M;Spethmann, S;Schreiner, M; Serum interleukin-6, procalcitonin, and C-reactive protein at hospital admission can identify patients at low risk for severe COVID-19 progression Frontiers in microbiology 2023-10-23 [PMID: 37937220] (Human)
• Walsh, RM;Ambrose, J;Jack, JL;Eades, AE;Bye, B;Ruckert, MT;Olou, AA;Messaggio, F;Chalise, P;Pei, D;VanSaun, MN; Adipose-Tumor Crosstalk contributes to CXCL5 Mediated Immune Evasion in PDAC bioRxiv : the preprint server for biology 2023-08-16 [PMID: 37645755] (Human)
• YY Wang, AC Hung, YC Wu, S Lo, HD Chen, YK Chen, YC Hsieh, SC Hu, MF Hou, SF Yuan ADSCs stimulated by resistin promote breast cancer cell malignancy via CXCL5 in a breast cancer coculture model Scientific Reports, 2022-09-14;12(1):15437. 2022-09-14 [PMID: 36104403] (Human)
• S Rutecki, P Szulc, M Paku?a, P Uruski, A Radziemski, E Naumowicz, R Moszy?ski, A Tykarski, J Miku?a-Pie, K Ksi??ek Pro-cancerogenic effects of spontaneous and drug-induced senescence of ovarian cancer cells in vitro and in vivo: a comparative analysis Journal of ovarian research, 2022-07-26;15(1):87. 2022-07-26 [PMID: 35883110] (Human)
• S Saxena, C Molczyk, A Purohit, E Ehrhorn, P Goel, DR Prajapati, P Atri, S Kaur, PM Grandgenet, MA Hollingswo, SK Batra, RK Singh Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinoma American journal of cancer research, 2022-01-15;12(1):68-90. 2022-01-15 [PMID: 35141005] (Human)
• HK Skovdahl, S Gopalakris, TD Svendsen, AVB Granlund, I Bakke, ZG Ginbot, S Thorsvik, A Flatberg, B Sporsheim, J Ostrop, TE Mollnes, AK Sandvik, T Bruland Patient Derived Colonoids as Drug Testing Platforms-Critical Importance of Oxygen Concentration Frontiers in Pharmacology, 2021-05-13;12(0):679741. 2021-05-13 [PMID: 34054553] (Human)
• GK Vasileiadi, AC Lundell, Y Zhang, K Andersson, I Gjertsson, A Rudin, C Maglio Adipocytokines in Untreated Newly Diagnosed Rheumatoid Arthritis: Association with Circulating Chemokines and Markers of Inflammation Biomolecules, 2021-02-21;11(2):. 2021-02-21 [PMID: 33669910] (Human)
• H Salvator, A Buenestado, M Brollo, E Naline, T Victoni, E Longchamp, H Tenor, S Grassin-De, P Devillier Clinical Relevance of the Anti-inflammatory Effects of Roflumilast on Human Bronchus: Potentiation by a Long-Acting Beta-2-Agonist Frontiers in Pharmacology, 2020-12-08;11(0):598702. 2020-12-08 [PMID: 33363471] (Human)
• X Ruiz-Plaza, E Rodríguez-, M Alves, A Altuna-Coy, J Lozano-Bar, M Portero-Ot, JF García-Fon, S Martínez-G, J Segarra, MR Chacón Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness J Transl Med, 2019-09-09;17(1):307. 2019-09-09 [PMID: 31500625] (Human)
• S Giuliano, M Dufies, PD Ndiaye, J Viotti, D Borchielli, J Parola, V Vial, Y Cormerais, M Ohanna, V Imbert, E Chamorey, N Rioux-Lecl, A Savina, JM Ferrero, B Mograbi, G Pagès Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5 Theranostics, 2019-01-30;9(4):1181-1199. 2019-01-30 [PMID: 30867824] (Human)
• U Kulkarni, RL Zemans, CA Smith, SC Wood, JC Deng, DR Goldstein Excessive neutrophil levels in the lung underlie the age-associated increase in influenza mortality Mucosal Immunol, 2019-01-07;12(2):545-554. 2019-01-07 [PMID: 30617300] (Mouse)
• B Ku?nar-Kam, J Miku?a-Pie, A Witucka, A Romaniuk, N Konieczna, B Rubi?, K Ksi??ek, A Tykarski, H Batura-Gab Serum from patients with chronic obstructive pulmonary disease induces senescence-related phenotype in bronchial epithelial cells Sci Rep, 2018-08-28;8(1):12940. 2018-08-28 [PMID: 30154415] (Human)
• T Hartwig, A Montinaro, S von Karste, A Sevko, S Surinova, A Chakravart, L Taraborrel, P Draber, E Lafont, F Arce Varga, MA El-Bahrawy, SA Quezada, H Walczak The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2 Mol. Cell, 2017-02-16;65(4):730-742.e5. 2017-02-16 [PMID: 28212753] (Human)
• Hongpeng Jia Pulmonary Epithelial TLR4 Activation Leads to Lung Injury in Neonatal Necrotizing Enterocolitis J Immunol, 2016-06-15;0(0):. 2016-06-15 [PMID: 27307558] (Human)
• Kachroo P, Lee M, Zhang L, Baratelli F, Lee G, Srivastava M, Wang G, Walser T, Krysan K, Sharma S, Dubinett S, Lee J IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res, 2013-11-25;32(0):97. 2013-11-25 [PMID: 24274066] (Human)
• Liu Y, Mei J, Gonzales L, Yang G, Dai N, Wang P, Zhang P, Favara M, Malcolm KC, Guttentag S, Worthen GS IL-17A and TNF-alpha Exert Synergistic Effects on Expression of CXCL5 by Alveolar Type II Cells In Vivo and In Vitro. J. Immunol., 2011-01-31;186(5):3197-205. 2011-01-31 [PMID: 21282514] (Human)
• Kovacikova M, Sengenes C, Kováčová Z, Siklova-Vitkova M, Klimcakova E, Polak J, Rossmeislova L, Bajzova M, Hejnova J, Hnevkovska Z, Bouloumie A, Langin D, Stich V Dietary intervention-induced weight loss decreases macrophage content in adipose tissue of obese women. Int J Obes (Lond), 2010-06-08;35(0):91-8. 2010-06-08 [PMID: 20531347] (Human)
• Hawn TR, Scholes D, Wang H, Li SS, Stapleton AE, Janer M, Aderem A, Stamm WE, Zhao LP, Hooton TM Genetic variation of the human urinary tract innate immune response and asymptomatic bacteriuria in women. PLoS ONE, 2009-12-15;4(12):e8300. 2009-12-15 [PMID: 20016852] (Human)
• Begley LA, Kasina S, Macdonald J, Macoska JA The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine, 2008-06-24;43(2):194-9. 2008-06-24 [PMID: 18572414] (Human)
• Wunder DM, Mueller MD, Birkhauser MH, Bersinger NA Increased ENA-78 in the follicular fluid of patients with endometriosis. Acta Obstet Gynecol Scand, 2006-01-01;85(3):336-42. 2006-01-01 [PMID: 16553183] (Human)
• Merck E, Gaillard C, Scuiller M, Scapini P, Cassatella MA, Trinchieri G, Bates EE Ligation of the FcR gamma chain-associated human osteoclast-associated receptor enhances the proinflammatory responses of human monocytes and neutrophils. J. Immunol., 2006-03-01;176(5):3149-56. 2006-03-01 [PMID: 16493074] (Human)

FAQs for CXCL5/ENA-78 (DY254). (Showing 1 - 1 of 1 FAQs).

1. wondering what the difference is between your quantikine and duo set elisas?
   • Usually the duosets do not have the entire kit such as plates and buffers, whereas the other kits are complete.

Bioinformatics

• Gene Symbol: CXCL5